US FDA’s Marks Issues ‘Provocative’ Call For Target Gene Therapy Profile That Includes Costs

 
• By Sarah Karlin-Smith

CBER Director Peter Marks said recent leaps in gene therapy science have not been matched by more affordable manufacturing technology and that the field needs to set a cost-effectiveness target. 

scientist holds 3d rendering of DNA molecule in hands.
The FDA's Peter Marks wants to lower the cost-effectiveness of gene therapy. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies